Science and Research

Currently treatments are largely insufficient, so care providers encourage more research despite stigma

Olorinab is a CB2 receptor agonist in a Phase 2 trial for IBS

And some terpenes have painkilling effects without interacting with cannabinoid receptors

Terpenes are only part of what gives some types of weed their unique smells and other related properties

The research casts doubt on currently used methods for detecting impairment

There are more than 3,800 studies on weed published this year already, surpassing a record set in 2020

Research funded by MindMed suggests some antidepressants can reduce the unwanted side effects of psychedelics

The methods will be available as part of third-party client services

Some are criticizing researcher Stamets for trying to capitalize on the phenomenon of 'stacking,' where psychedelics are paired with health supplements

Cannabis and 'classical' psychedelics could act on similar receptors

While there's only limited data on the effects of cannabis in minors, researchers suggest it as an alternative to surgery in severe cases

But terpenes might be tempering the process

Several of the common smell-producing compounds in cannabis are associated with analgesic properties, and have attractive safety profiles

It’s the first federal grant to be awarded for psychedelic treatment research in 50 years

Taking sublingual oils proved beneficial for chronic pain, nausea, anxiety and a list of other common ailments

On average, unregulated bud tested had 10%-lower THC than advertised

A study linked self reports of being stoned with time and movement in young adults

The research relied on an inaccurate timeframe and didn't distinguish between legal and illegal products, critics say

Researchers say their intention isn't to fearmonger, but to educate the public on potential risks

Concerns were raised that cannabis would spike accidents, especially among youth, but data show otherwise

The agency says it supports research into the substances and it's necessary for the FDA to approve new quotas

According to Canadian researchers, cannabis can help people cut the country's most fatal dependency

A 5-year project led by university researchers will study pot as a treatment for opioid use and dependency on methadone or suboxone

In a new study, two popular detection devices never mistook CBD for THC

Surveys from pre- and post-legalization show that heavy consumers are less likely to buy legal Canadian weed due to cost and access

By perpetuating false narratives about fentanyl, lives are put at risk, advocates argue

Researchers are looking at the potential pros and cons of cannabis use on procreative fitness

An international team of scientists discovered that all modern-day pot evolved from 'basal cannabis', first smoked in ancient China more than 12,000 years ago

Current naming conventions have added confusion to the poorly understood genetic background of the thousands of varieties in existence today

The psychedelic movement is no longer about anecdotes, experts say

Results come from the IMAGEN study, a large sample group tracked over time in 4 European countries

Cannabis smokers inhale 'significantly' less harmful chemicals than tobacco smokers, but are still not without some risk

After drinking the psychedelic plant brew together, Jewish-Israeli and Arab-Palestinian participants reported moments of deep connection, unity and oneness

Following the successful MAPS study, MDMA-assisted therapy moves closer to becoming approved by the US FDA

Aside from impairment testing, Ontario-based Zentrela wants to work with cannabis producers to generate accurate product claims

Study aims to prove safety of psilocybe mushrooms so Canadian regulators can expand access to psychedelic therapy

Identifying specific terpene-cannabinoid combinations can create new ways to improve medical therapy, researchers suggest

More alcohol, but not weed, use during youth is associated with thinning in parts of the brain associated with intelligence, impulsivity and risky behaviour

The first head-to-head clinical trial pushes the psychedelic compound closer to becoming a licensed medicine

The resource-rich country produces less emissions than the US, but it's still a big problem that government isn't tracking and firms don't want to talk about